Literature DB >> 15479242

Effects of cardiomyopathic mutations on the biochemical and biophysical properties of the human alpha-tropomyosin.

Eduardo Hilario1, Silvia L F da Silva, Carlos H I Ramos, Maria Célia Bertolini.   

Abstract

Mutations in the protein alpha-tropomyosin (Tm) can cause a disease known as familial hypertrophic cardiomyopathy. In order to understand how such mutations lead to protein dysfunction, three point mutations were introduced into cDNA encoding the human skeletal tropomyosin, and the recombinant Tms were produced at high levels in the yeast Pichia pastoris. Two mutations (A63V and K70T) were located in the N-terminal region of Tm and one (E180G) was located close to the calcium-dependent troponin T binding domain. The functional and structural properties of the mutant Tms were compared to those of the wild type protein. None of the mutations altered the head-to-tail polymerization, although slightly higher actin binding was observed in the mutant Tm K70T, as demonstrated in a cosedimentation assay. The mutations also did not change the cooperativity of the thin filament activation by increasing the concentrations of Ca2+. However, in the absence of troponin, all mutant Tms were less effective than the wild type in regulating the actomyosin subfragment 1 Mg2+ ATPase activity. Circular dichroism spectroscopy revealed no differences in the secondary structure of the Tms. However, the thermally induced unfolding, as monitored by circular dichroism or differential scanning calorimetry, demonstrated that the mutants were less stable than the wild type. These results indicate that the main effect of the mutations is related to the overall stability of Tm as a whole, and that the mutations have only minor effects on the cooperative interactions among proteins that constitute the thin filament.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479242     DOI: 10.1111/j.1432-1033.2004.04351.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Investigating the effects of tropomyosin mutations on its flexibility and interactions with filamentous actin using molecular dynamics simulation.

Authors:  Wenjun Zheng; Sarah E Hitchcock-DeGregori; Bipasha Barua
Journal:  J Muscle Res Cell Motil       Date:  2016-07-04       Impact factor: 2.698

2.  Combinatorial effects of double cardiomyopathy mutant alleles in rodent myocytes: a predictive cellular model of myofilament dysregulation in disease.

Authors:  Jennifer Davis; Joseph M Metzger
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

3.  Cardiomyopathy Mutation Alters End-to-End Junction of Tropomyosin and Reduces Calcium Sensitivity.

Authors:  SaiLavanyaa Sundar; Michael J Rynkiewicz; Anita Ghosh; William Lehman; Jeffrey R Moore
Journal:  Biophys J       Date:  2019-12-14       Impact factor: 4.033

4.  Familial hypertrophic cardiomyopathy related E180G mutation increases flexibility of human cardiac α-tropomyosin.

Authors:  Campion K P Loong; Huan-Xiang Zhou; P Bryant Chase
Journal:  FEBS Lett       Date:  2012-08-14       Impact factor: 4.124

5.  Tropomyosin flexural rigidity and single ca(2+) regulatory unit dynamics: implications for cooperative regulation of cardiac muscle contraction and cardiomyocyte hypertrophy.

Authors:  Campion K P Loong; Myriam A Badr; P Bryant Chase
Journal:  Front Physiol       Date:  2012-04-04       Impact factor: 4.566

6.  Integrative structural modelling of the cardiac thin filament: energetics at the interface and conservation patterns reveal a spotlight on period 2 of tropomyosin.

Authors:  S Margaret Sunitha; John A Mercer; James A Spudich; Ramanathan Sowdhamini
Journal:  Bioinform Biol Insights       Date:  2012-10-03

7.  α-Tropomyosin with a D175N or E180G mutation in only one chain differs from tropomyosin with mutations in both chains.

Authors:  Miro Janco; Athanasia Kalyva; Beatrice Scellini; Nicoletta Piroddi; Chiara Tesi; Corrado Poggesi; Michael A Geeves
Journal:  Biochemistry       Date:  2012-11-30       Impact factor: 3.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.